Chronic Heart Failure | Treatment Algorithms | Claims Data Analysis | US | 2017 November
First-line treatment of chronic heart failure (CHF) usually involves a beta blocker, an angiotensin-converting enzyme (ACE) inhibitor, and an oral diuretic. Second- or third-line treatments are often needed to better manage the disease. Physicians have numerous drug classes to choose from, most of which consist of drug options. The CHF market is heavily genericized, as such physician practice is minimally impacted by pricing pressures. The CHF Treatment Algorithm offers insight into prescribing patterns in this multi-layered treatment landscape where few branded agents jostle for patient share in a crowded sector. That said, small patient shares for such a prevalent indication can translate into significant commercial positions.
Related Market Assessment Reports
Report
Chronic Obstructive Pulmonary Disease – Unmet Need – Unmet Need – Severe to Very Severe Chronic Obstructive Pulmonary Disease (US EU)
The severe to very severe chronic COPD market is crowded, with numerous LAMA, LABA/ICS, LABA/LAMA, and triple LABA/LAMA/ICS inhalers competing for use. Although dual and triple longacting…
Report
Diabetic Macular Edema / Diabetic Retinopathy – Current Treatment – Treatment Algorithms: Claims Data Analysis – Diabetic Macular Edema (US)
Diabetic macular edema (DME) is a serious complication of diabetic retinopathy caused by persistently elevated blood glucose levels. Without timely treatment, DME can progress to significant vision…
Report
Multiple System Atrophy – Unmet Need – Multiple System Atrophy (US/EU) – Unmet Need – Multiple System Atrophy (US/EU)
Multiple system atrophy (MSA) is a rare, rapidly progressing neurodegenerative synucleinopathy that disrupts movement, balance, and autonomic function. Current management comprises only symptomatic…
